Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
indiana blog main
indiana top stories
5
×
life sciences
national blog main
new york blog main
new york top stories
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
national
national top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
fda
spark therapeutics
alnylam pharmaceuticals
amgen
amicus therapeutics
cancer
cystic fibrosis
deals
diagnostics
europe blog main
europe top stories
gene therapy
What
drug
5
×
patients
5
×
bio
fda
roundup
market
type
acquisitions
advantages
albert
approval
aren’t
bar
bid
biggest
boehringer
bourla
brings
cancer
ceo
company
crispr
developers
diabetes
drugs
eisai
eli
expand
expect
fallen
flags
future
gamble
gene
help
higher
imminent
imports
incidence
ingelheim
Language
unset
unknown
Current search:
drug
×
patients
×
" indiana top stories "
×
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More